{"id":973882,"date":"2026-06-18T21:44:16","date_gmt":"2026-06-19T01:44:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/"},"modified":"2026-06-18T21:44:16","modified_gmt":"2026-06-19T01:44:16","slug":"novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/","title":{"rendered":"Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <i> Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday on June 18, 2026. <\/i>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\">NEW YORK,<\/span>, <span class=\"legendSpanClass\">June 18, 2026<\/span> \/PRNewswire\/ &#8212; Investors who held Novocure Limited (NASDAQ: NVCR) shares lost more than $3 per share on June 18, 2026, when the stock had fallen over 18% in a single session. Shareholders who suffered a loss are encouraged to <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4715336-2&amp;h=1352351638&amp;u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fnovocure-limited-investigation-nvcr%3Fprid%3D189076%26wire%3D4&amp;a=submit+their+information+now+\" target=\"_blank\" rel=\"nofollow\">submit their information now <\/a>. You may also contact Joseph E. Levi, Esq. via email at <a href=\"mailto:jlevi@SueWallSt.com\" target=\"_blank\" rel=\"nofollow\">jlevi@SueWallSt.com <\/a>or by telephone at (888) SueWallSt.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <img decoding=\"async\" src=\"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1_Logo.jpg?id=OA2725620\" title=\"SueWallSt.com\" alt=\"SueWallSt.com\" \/>\n        <\/p>\n<\/p><\/div>\n<p>On its Q3 2025 earnings call, then-CEO Ashley Cordova indicated TRIDENT was examining &#8220;the benefit of starting Tumor Treating Fields concurrently with chemo radiation in newly diagnosed GBM,&#8221; as opposed to the current practice of waiting until after the &#8220;chemo radiation cycle ends.&#8221; On January 14, 2026, during Novocure&#8217;s presentation at a healthcare conference, CEO Frank Leonard indicated they expected, for the majority of patients in the study, that &#8220;we&#8217;ll produce better duration of therapy overall than in our prior study.&#8221; He further claimed, with respect to the upcoming readouts, that the company had put itself &#8220;in a place to build additional evidence over the coming years to keep this growth going.&#8221;<\/p>\n<p>Several months later, on June 18, 2026, shares were falling more than 18% midday after the Company disclosed that its Phase 3 TRIDENT trial missed the primary overall survival endpoint, wiping out roughly $3.30 per share in value.<\/p>\n<p>Shareholders who lost money on their NVCR investment are encouraged to <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4715336-2&amp;h=1083640856&amp;u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fnovocure-limited-investigation-nvcr%3Fprid%3D189076%26wire%3D4&amp;a=click+here+to+discuss+their+legal+rights+\" target=\"_blank\" rel=\"nofollow\">click here to discuss their legal rights <\/a>. You may also contact Joseph E. Levi, Esq. via email at <a href=\"mailto:jlevi@SueWallSt.com\" target=\"_blank\" rel=\"nofollow\">jlevi@SueWallSt.com <\/a>or by telephone at (888) SueWallSt.<\/p>\n<p>SueWallSt &#8212; Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.<\/p>\n<p>Frequently Asked Questions About the NVCR Investigation<\/p>\n<p>\n        <b> Q: Who is eligible to participate in the NVCR investigation? <\/b>A: Investors who purchased NVCR stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses &#8212; not on whether you still hold the shares.<\/p>\n<p>\n        <b> Q: How much did NVCR stock drop? <\/b>A: Shares had collapsed more than 18%, a decline of rover $3 per share, after the Company disclosed that its Phase 3 TRIDENT glioblastoma trial missed the primary overall survival endpoint. Investors who purchased shares at elevated prices may be entitled to compensation.<\/p>\n<p>\n        <b> Q: What do NVCR investors need to do right now? <\/b>A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at <a href=\"mailto:jlevi@SueWallSt.com\" target=\"_blank\" rel=\"nofollow\">jlevi@SueWallSt.com <\/a>or (888) SueWallSt. No immediate action is required to remain eligible to participate in the investigation.<\/p>\n<p>\n        <b> Q: What happens after I contact SueWallSt? <\/b>A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.<\/p>\n<p>\n        <b> Q: What if I already sold my NVCR shares &#8212; can I still recover losses? <\/b>A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NVCR and sold at a loss may still participate in the investigation.<\/p>\n<p>\n        <b> Q: What does it cost me to participate? <\/b>A: Nothing. Securities investigations are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.<\/p>\n<p>CONTACT:<br \/>SueWallSt<br \/>Joseph E. Levi, Esq.<br \/>Ed Korsinsky, Esq.<br \/>33 Whitehall Street, 27th Floor<br \/>New York, NY 10004<br \/><a href=\"mailto:jlevi@SueWallSt.com\" target=\"_blank\" rel=\"nofollow\">jlevi@SueWallSt.com<\/a><br \/>Tel: (888) SueWallSt<br \/>Fax: (212) 363-7171<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=NY87694&amp;sd=2026-06-18\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr-302804902.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr-302804902.html<\/a><\/p>\n<p>SOURCE SueWallSt.com<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY87694&amp;Transmission_Id=202606182141PR_NEWS_USPR_____NY87694&amp;DateId=20260618\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday on June 18, 2026. NEW YORK,, June 18, 2026 \/PRNewswire\/ &#8212; Investors who held Novocure Limited (NASDAQ: NVCR) shares lost more than $3 per share on June 18, 2026, when the stock had fallen over 18% in a single session. Shareholders who suffered a loss are encouraged to submit their information now . You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt. On its Q3 2025 earnings call, then-CEO Ashley Cordova indicated TRIDENT was examining &#8220;the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-973882","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday on June 18, 2026. NEW YORK,, June 18, 2026 \/PRNewswire\/ &#8212; Investors who held Novocure Limited (NASDAQ: NVCR) shares lost more than $3 per share on June 18, 2026, when the stock had fallen over 18% in a single session. Shareholders who suffered a loss are encouraged to submit their information now . You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt. On its Q3 2025 earnings call, then-CEO Ashley Cordova indicated TRIDENT was examining &#8220;the &hellip; Continue reading &quot;Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-19T01:44:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1_Logo.jpg?id=OA2725620\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)\",\"datePublished\":\"2026-06-19T01:44:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\\\/\"},\"wordCount\":586,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1_Logo.jpg?id=OA2725620\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\\\/\",\"name\":\"Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1_Logo.jpg?id=OA2725620\",\"datePublished\":\"2026-06-19T01:44:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1_Logo.jpg?id=OA2725620\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1_Logo.jpg?id=OA2725620\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/","og_locale":"en_US","og_type":"article","og_title":"Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - Market Newsdesk","og_description":"PR Newswire Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday on June 18, 2026. NEW YORK,, June 18, 2026 \/PRNewswire\/ &#8212; Investors who held Novocure Limited (NASDAQ: NVCR) shares lost more than $3 per share on June 18, 2026, when the stock had fallen over 18% in a single session. Shareholders who suffered a loss are encouraged to submit their information now . You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt. On its Q3 2025 earnings call, then-CEO Ashley Cordova indicated TRIDENT was examining &#8220;the &hellip; Continue reading \"Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-19T01:44:16+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1_Logo.jpg?id=OA2725620","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)","datePublished":"2026-06-19T01:44:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/"},"wordCount":586,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1_Logo.jpg?id=OA2725620","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/","name":"Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1_Logo.jpg?id=OA2725620","datePublished":"2026-06-19T01:44:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1_Logo.jpg?id=OA2725620","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1_Logo.jpg?id=OA2725620"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-limited-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-novocure-limited-nvcr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/973882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=973882"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/973882\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=973882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=973882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=973882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}